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Abstract
Background: Oxidative stress plays a potential role in the pathogenesis and progression of
chronic obstructive pulmonary disease (COPD). Glutathione S-transferases (GSTs) detoxify toxic
compounds in tobacco smoke via glutathione-dependent mechanisms. Little is known about the
regulation and expression of GSTs in COPD lung and their presence in airway secretions.
Methods: GST alpha, pi and mu were investigated by immunohistochemistry in 72 lung tissue
specimens and by Western analysis in total lung homogenates and induced sputum supernatants
from non-smokers, smokers and patients with variable stages of COPD severity.
Results: GST alpha was expressed mainly in the airway epithelium. The percentage of GST alpha
positive epithelial cells was lower in the central airways of patients with very severe (Stage IV)
COPD compared to mild/moderate COPD (p = 0.02). GST alpha by Western analysis was higher
in the total lung homogenates in mild/moderate COPD compared to cases of very severe disease
(p < 0.001). GST pi was present in airway and alveolar epithelium as well as in alveolar
macrophages. GST mu was expressed mainly in the epithelium. Both GST alpha and pi were
detectable in sputum supernatants especially in patients with COPD.
Conclusion: This study indicates the presence of GST alpha and pi especially in the epithelium and
sputum supernatants in mild/moderate COPD and low expression of GST alpha in the epithelium
in cases of very severe COPD. The presence of GSTs in the airway secretions points to their
potential protective role both as intracellular and extracellular mediators in human lung.
Background
Epithelial lining fluid (ELF) contains more than 140-fold
higher levels of glutathione (GSH) (L--glutamyl-L-cystei-
nyl-glycine) compared to plasma, evidence of its critical
role in protecting airway epithelium from oxidant injury
[1,2]. Glutathione S-transferases (GSTs) consist of a super-
family of dimeric phase II metabolic enzymes that cata-
lyze the conjugation of reduced GSH with electrophilic
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compounds e.g. detoxifing toxic components of tobacco
smoke. They are mainly regulated by nuclear factor, eryth-
roid-derived 2, like 2 (Nrf2), a transcription factor that
contributes to the induction of several protective enzymes
during oxidative stress [3-5]. In experimental animals
exposed to cigarette smoke, inhibition of this system in
turn leads to emphysema [6,7], another indicator of the
importance of this mechanism and related enzymes such
as GSTs in the prevention of chronic obstructive pulmo-
nary disease (COPD)/emphysema. The protein levels of
several GSTs with the exception of GST omega [8] have
not been investigated in human COPD. Furthermore, lit-
tle is known about their possible presence in airway secre-
tions of healthy or COPD lung. Given the high levels of
GSH in the epithelial lining fluid, intracellular vs extracel-
lular GSH homeostasis may be partly regulated by the
GSTs, enzymes that participate both in GSH transport and
detoxification reactions.
There are a number of GST isoenzymes including GST
alpha (GSTA), mu (GSTM), pi (GSTP), omega, theta,
sigma, and kappa. In proximal airways, GST pi, mu and
alpha have been found in the brush border and GST pi
and mu but not GST alpha in alveolar cells and macro-
phages [9] while other GSTs have not been investigated in
the peripheral lung. The RNA levels of GSTA2 and GSTP1
are elevated in the bronchial epithelium of smokers but
no such difference has been found for GSTM1 [10,11]. As
far as we are aware there is only one microarray study on
the RNA levels of antioxidant enzymes including GSTs in
the bronchial brushings of COPD patients, which indi-
cated that though the RNA expression of these enzymes
may change, there does not seem to be a linear correlation
with COPD severity [12].
Genetic polymorphisms of xenobiotic metabolizing
enzymes including GSTs have been shown to associate
with COPD in many previous investigations. GSTP1 gene
polymorphism correlates with susceptibility to COPD
[13] and homozygous deletion of the GSTM1 gene is asso-
ciated with emphysema in patients who have lung cancer
[14] and with chronic bronchitis in heavy cigarette smok-
ers [15]. Polymorphism of GSTO2, is associated with low
lung function values [16]. The GSTM1, GSTT1 null, and
GSTP1 Val/Val have been linked with increased risk (12-
fold) for COPD [17] and GSTT1 deficiency in combina-
tion with GSTM1 deficiency independently appears to be
associated with an accelerated age-related decline of lung
function in males irrespective of smoking [18]. Most of
these studies on GST polymorphisms highlight the impor-
tance of these enzymes in protection against the oxidative
stress induced by cigarette smoke.
This study was undertaken 1) to investigate the distribu-
tion and expression of GSTs in normal human lung and
COPD of various severities both in proximal airways and
in peripheral lung tissue and 2) to study the expression of
the GSTs in induced sputum cells and supernatants in
healthy individuals and patients with COPD.
Materials and methods
Lung tissue specimens
Lung tissue specimens from 72 patients (16 life-long non-
smokers, 26 current smokers with mild-to-moderate
COPD, 22 current smokers with normal lung function)
operated on for local lung tumour (malignant and non-
malignant such as hamartomas) and 8 ex-smokers with
very severe (Stage IV) COPD undergoing lung transplan-
tation formed the basis for immunohistochemical studies
from Oulu and Helsinki University Hospitals. Tissue spec-
imens from tumor-free resection line and from the
peripheral lung tissue were selected. COPD was defined
on the basis of preoperative lung function: FEV1/FVC less
than 70% and no reversibility (bronchodilatation effect
less than 12%). The patients were not receiving corticos-
teroid therapy (neither inhaled nor systemic) with the
exception of the lung transplantation cases. The clinical
characteristics were obtained from the patient records
(Table 1).
Lung tissue specimens from peripheral lung tissue for the
Western analyses had been frozen immediately after the
surgery in liquid nitrogen. They were homogenized in ice
cold phosphate buffered saline (PBS), used for Western
analysis and evaluated for the total level of GSTs alpha,
mu and pi in the lung. (Table 2).
Induced sputum
Induced sputum samples from 3 healthy non-smokers, 3
symptomatic smokers (chronic bronchitis) and 6 smokers
with COPD formed the material for sputum experiments.
Table 1: Patient characteristics of the specimens examined by 
immunohistochemistry
Non-smoker
N = 16
Smoker
N = 22
COPD
N = 34
p-value
Age, years 65 (13) 63 (8) 62 (9) 0.543
Sex M:F 8:8 17:5 27:7 0.103
Pack-years 0 46 (19)* 38 (13)§ 0.000
FEV1 %predicted 98 (15) 90 (10) 55 (23)*# 0.000
FEV1/FVC % 86 (9) 83 (11) 56 (15)*# 0.000
MEF50 %pred 94 (24) 80 (37) 34 (21)*# 0.000
DCO %pred 91 (15) 78 (14) 64 (27)§ 0.004
DCO/VA %pred 89 (11) 83 (12) 72 (24) § 0.035
Mean (SD)
*The mean difference between non-smokers and smokers is 
significant at the 0.05 level, Dunnett t-test.
§The mean difference between non-smokers and COPD-patients is 
significant at the 0.05 level, Dunnett t-test.
# The mean difference between smokers and COPD-patients is 
significant at the 0.05 level, Dunnett t-test.Respiratory Research 2008, 9:80 http://respiratory-research.com/content/9/1/80
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Sputum was induced by inhalation of 4.5% hypertonic
saline given at 5-minute intervals for a maximum of 20
minutes according to the guidelines of the European Res-
piratory Society's Task Force [19]. The characteristics of
the patients selected for the studies on induced sputum
specimens are shown in Table 3.
Immunohistochemistry
The sections were deparaffinized in xylene and rehydrated
in a descending ethanol series. Endogenous peroxidase
was blocked by incubating the sections in 3% hydrogen
peroxide in absolute methanol for 15 minutes. The sec-
tions were incubated with the primary polyclonal antirab-
bit antibodies for GST mu (1:100), GST pi (1:100) or GST
alpha 1:75 (Acris Antibodies, Hiddenhausen, Germany).
The immunostaining was done using the Histostain-Plus
Kit (Zymed Laboratories Inc., San Francisco, CA), and the
chromogen was aminoethyl carbazole (AEC) (Zymed
Laboratories Inc.). In negative controls, the primary anti-
body was substituted with phosphate-buffered saline
(PBS) or rabbit primary antibody isotype control from
Zymed Laboratories Inc.
For GST alpha, GST mu and GST pi, the immunoreactivity
was assessed semiquantitatively from all fields of one sec-
tion of central and peripheral lung by separately grading
the staining intensity of the macrophages, bronchial,
bronchiolar or alveolar epithelium or vascular endothe-
lium as negative (0), weak (1) or moderate (2) or intense
(3) (YS). For GST alpha, the immunoreactivity was con-
centrated in the airway epithelium and the grading of GST
alpha immunoreactivity was quantified by estimating the
percent of positive epithelial cells (YS).
Immunocytochemistry of GST alpha in induced sputum
cells was performed as previously described by Peltoniemi
M et al [20]. The cytospin samples were treated with
Ortho Permeafix (Ortho Diagnostic Systems Inc., UK) and
for immunostaining, Zymed ABC Histostain-Plus Kit was
used according to the manufacturer's protocol. The sam-
ples were incubated with an antibody against GST alpha
and negative control samples with Zymed Rabbit Isotype
Control and PBS, and stained with AEC (Zymed Labora-
tories Inc.) and thereafter with Mayer's haematoxylin.
Western analysis
The cell pellets were resuspended in sterile water contain-
ing protease inhibitors, Complete Mini tablets (Roche,
Mannheim, Germany) and cells were lysed by sonicating.
The protein concentrations were measured using the DC
protein assay from Bio-Rad (Bio-Rad Laboratories, Her-
cules, CA, USA) and 40 g of cell protein was applied per
lane to a 12% sodium dodecyl sulphate-polyacrylamide
gel (SDS-PAGE) and electrophoresed as described [20].
Due to the major changes in the classical constitutive pro-
teins that have been generally used as loading controls
[21-23], here the equal loading was ensured by Ponceau
protein assay after careful protein determinations. Mem-
branes were incubated with primary antibodies against
Table 2: Patient characteristics in the specimens examined by 
Western analysis.
Non-smoker
N = 7
Smoker
N = 7
COPD
N = 16
p-value
Age, years 63 (13) 59 (4) 62 (10) 0.754
Sex M:F 4:3 5:2 12:4 0.688
Pack-years 0 36 (16)* 34 (17)§ 0.000
FEV1 %predicted 88 (18) 88 (13) 55 (31)*# 0.005
FEV1/FVC % 83 (9) 83 (10) 57 (20)*# 0.000
MEF50 %pred 88 (35) 84 (61) 37 (22) 0.066
DCO %pred 95 (20) 82 (10) 52 (22)§ 0.003
DCO/VA %pred 100 (18) 89 (9) 62 (24) § 0.006
Mean (SD)
All cases were studied for the expression of GST pi, but due to the 
exhaustion of biopsy material, only 4 non-smokers, 3 smokers and 8 
COPD-cases were included in the Western analysis for GST alpha 
expression and 4 smokers, 4 non-smokers and 10 COPD-patients for 
GST mu expression.
*The mean difference between non-smokers and smokers is 
significant at the 0.05 level, Dunnett t-test.
§ The mean difference between non-smokers and COPD-patients is 
significant at the 0.05 level, Dunnett t-test.
# The mean difference between smokers and COPD-patients is 
significant at the 0.05 level, Dunnett t-test.
Table 3: The characteristics of the patients providing sputum samples
Non-smoker
N = 3
Chronic bronchitis
N = 3
COPD
N = 6
p-value
Age, years 45 (21) 44 (16) 60 (7) 0.181
Sex M:F 3:0 3:0 4:2 0.301
Pack-years 0 29 (15) 48 (18) 0.005
FEV1 %predicted 113 (19) 101 (4) 61 (21) 0.021
FEV1/FVC % 88 (2) 80 (1) 64 (15) 0.115
MEF50 %pred 131 (47) 87 (12) 36 (20) 0.006
DCO %pred 92 (7) 95 (6) 63 (24) 0.053
DCO/VA %pred 100 (5) 99 (8) 75 (31) 0.266
Mean (SD)Respiratory Research 2008, 9:80 http://respiratory-research.com/content/9/1/80
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GST alpha, mu and pi (dilution 1:4000 for GST alpha,
1:2000 for GST pi and 1:1000 for GST mu) for 3 hours fol-
lowed by treatment with secondary antibodies over night
in +4°C. Protein bands were detected with Immobilon
detection solution (Millipore, Billerica, MA, USA) and the
luminal excitation was imaged on x ray film (Amersham
Biosciences, Buckinghamshire, UK). Quantification of the
band sum intensity was used the Kodak 1D Scintific
Image Analysis System (Eastman Kodak Company, New
Haven, Connecticut, USA).
Statistical methods
The statistical analyses were performed with the SPSS for
Windows software (SPSS, Chicago, IL, USA). Continuous
data were compared using analysis of variance (ANOVA).
When ANOVA results indicated that groups differed, post
hoc comparisons were performed using two-tailed t-tests.
Categorical data were compared using Fisher exact test
designed for small sample groups. P-values less than 0.05
were considered statistically significant.
Ethical considerations
The study protocol was accepted by the ethical committee
of the University of Oulu and Oulu University Hospital
and the ethical board of Helsinki University Hospital and
it is in accordance with the ethical standards of the Hel-
sinki declaration of 1975.
Immunohistochemical staining for GST alpha in specimens from the central and peripheral lung of a non-smoker (A and B,  respectively), a smoker (C and D), and patients with Stage I-II COPD (E and F) and Stage IV COPD (G and H) Figure 1
Immunohistochemical staining for GST alpha in specimens from the central and peripheral lung of a non-
smoker (A and B, respectively), a smoker (C and D), and patients with Stage I-II COPD (E and F) and Stage IV 
COPD (G and H). GST alpha was mainly located in the airway epithelium.Respiratory Research 2008, 9:80 http://respiratory-research.com/content/9/1/80
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Results
GST alpha
GST alpha was mainly localized in the central and periph-
eral airway epithelium, with some alveolar macrophages
showing weak positivity (Figure 1). The intensity of GST
alpha staining showed a tendency to be lower in the cen-
tral airways of cases of very severe (Stage IV) COPD com-
pared to Stage I-II COPD. Moreover, the percentage of
GST alpha positive epithelial cells was significantly lower
in the central airway epithelium of Stage IV COPD than in
Stage I-II COPD (p = 0.02). No corresponding changes
could be seen in the peripheral airway epithelium (Figure
2A, B). When the total immunoreactivity was assessed by
Western analysis of the lung homogenate, GST alpha was
higher in Stage I-II COPD (p < 0.001) than in Stage IV
COPD (Figure 2C). Additionally, GST alpha was clearly
detectable in induced sputum supernatants, being higher
both in chronic bronchitis and in Stage II-III COPD than
in the healthy non-smokers (Figure 3) (p < 0.001). The
Western blotting of GST alpha consistently showed two
bands from the tissues but not from sputum supernatants.
These results can be related to many reasons one of those
being proteolysis of GST alpha in the tissues. Another,
even more likely reason is the presence of various alpha-
class GSTs in human lung tissues but not in sputum super-
natants. Two GST alpha subtypes have been earlier docu-
mented in rat tissue homogenates and porcine Sertoli cells
and our results are in full agreement with those investiga-
tions [24,25]. In induced sputum cytospins, GST alpha
was localized in macrophages (Figure 3). Induced sputum
was not collected from very severe cases partly due to tech-
nical difficulties, only lung tissue specimens were availa-
ble from the cases of very severe COPD.
GST pi
GST pi was present in the epithelium of airways and alve-
oli and in approximately 5% of alveolar macrophages.
The immunoreactivity or the number of GST pi positive
cells did not differ between the various COPD severities.
When lung tissue homogenates were evaluated by West-
ern analysis, GST pi was higher in Stage I-II COPD com-
pared to healthy smokers (p = 0.002) (Figure 4A,B). GST
pi could also be detected from the sputum supernatants
but there were no significant differences between controls
and COPD patients.
GST mu
GST mu was located in the macrophages, bronchial and
alveolar epithelium. Western analysis of the lung
homogenates for GST mu exhibited some variability (Fig-
ure 4C,D) but the changes were minor and not significant
(p = 0.063). Sputum supernatant was negative for GST mu
in the Western blot analyses, but this negative finding
does not exclude its presence in airway secretions.
Discussion
The results of the present investigation extend previous
knowledge about GSTs and human lung which so far have
mainly focused on the polymorphisms in these enzymes
in protecting human lung against toxic metabolites [26]
or the mRNA levels of these enzymes in the bronchial
brushings of smokers or COPD patients [11,12]. Here the
actual GST proteins were expressed in large and peripheral
airways, where the levels of GST alpha were low in the
large airways of cases with very severe (Stage IV) COPD.
We present another new finding which may have impor-
tant role in the interpretation of the antioxidant defense
of airway epithelial lining fluid in general, i.e. the pres-
ence GST alpha in particular in sputum supernatants and
its further elevation in chronic bronchitis and COPD.
There was clear immunoreactivity of GST alpha in sputum
macrophages but the staining positivity cannot exclude
the possibility that macrophages may also have ingested
GST alpha positive material from the epithelial lining
fluid/sputum supernatant. In patients with very severe dis-
ease, the decline of GST activity can significantly worsen
the imbalance between oxidants and GSH associated
detoxification mechanisms in the airways.
Our findings are in line with the results of the microarray
analysis performed by Hackett et al. describing upregula-
tion of GST A2 RNA in airway epithelium of smokers [11].
In that particular study, no changes in GST M3, M4 or GST
pi RNA expression could be observed. In a recent study,
also GSTM3 gene expression was upregulated in healthy
smokers and in COPD compared to healthy smokers [12].
However, the RNA level did not increase linearly as the
disease progressed. It is known that the RNA level does
not necessarily correlate with the protein or functional
activity. In the study of Pierrou and co-workers for exam-
ple, levels of CYP1B1 RNA but not the immunoreactive
protein were elevated in the bronchial brushings of COPD
patients. The present study on several GSTs revealed the
most marked immunoreactivity and greatest changes in
GST alpha in COPD. The strength of our study is the large
material including non-smokers, smokers and patients in
different stages of COPD, with specimens from central
and peripheral airways, pointing to the importance of
GSTs, especially GST alpha against smoking induced oxi-
dative stress. This study confirms our previous findings,
that the protein levels of many antioxidant enzymes
which are involved in GSH homeostasis of the lung do
not increase linearly as the disease progresses and may
even be downregulated as the disease progresses to termi-
nal stages [8,20,27]. Whether the immunoreactivity of a
specific GST correlates with the corresponding isoenzyme
activity remains unclear. The COPD Stage IV patients were
ex-smokers whereas Stage I-II COPD cases were current
smokers. Further studies will be needed to evaluate theRespiratory Research 2008, 9:80 http://respiratory-research.com/content/9/1/80
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Figure 2 (see legend on next page)Respiratory Research 2008, 9:80 http://respiratory-research.com/content/9/1/80
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effects of smoking cessation in this and other protective
GST alpha expression in the airways and in total lung homogenates Figure 2 (see previous page)
GST alpha expression in the airways and in total lung homogenates. A. The GST alpha immunoreactivity in airway 
epithelium of central and peripheral airways. The staining was graded as negative (0), weak (1) or moderate (2) or intense (3). 
The GST alpha immunoreactivity was strong in the epithelium of both large, cartilaginous airways as well as in the epithelium of 
small peripheral bronchioli. There was a trend for diminished immunoreactivity in cases of very severe (Stage IV) COPD but 
the difference between the groups was not statistically significant. The means are shown as columns with error bars represent-
ing SEM. B. The percentage of GST alpha positive epithelial cells was observed to decrease in the large airways of the patients 
with very severe (Stage IV) COPD compared to non-smokers (p = 0.02). C. Western analysis of GST alpha in the lung 
homogenates of healthy non-smokers and smokers and in patients with different stages of COPD showed an increased immu-
noreactivity in patients with Stage I-II COPD compared to non-smokers or smokers (p = 0.007). The means of the measured 
sum intensities are shown as columns with error bars representing SEM.
GST alpha immunoreactivity in sputum cells and supernatants Figure 3
GST alpha immunoreactivity in sputum cells and supernatants. A. Western analysis for GST alpha in induced sputum 
supernatants revealed an increased immunoreactivity in patients with chronic bronchitis and in Stage II-III COPD compared to 
healthy non-smokers (p < 0.001). The means of the measured intensities are shown as columns with error bars representing 
SEM. B. Representative sputum cytospins from a smoker (a), patient with chronic bronchitis (b) and patient with Stage II COPD 
(c). Macrophages in the induced sputum exhibited positive GST alpha reactivity.Respiratory Research 2008, 9:80 http://respiratory-research.com/content/9/1/80
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enzymes in human lung.
The levels of GST alpha decreased in very severe COPD.
This is in agreement with earlier studies with GST omega
[8], glutaredoxin [20] and the rate limiting enzyme in the
synthesis of GSH i.e. glutamate-cysteine ligase [27]. All
these enzymes are regulated by a Nrf2 related mechanism,
where Nrf2, Keap1 and the Nrf2 stabilizer DJ-1 are
involved. Importantly, a recent study on these mecha-
nisms in COPD revealed a decline in Nrf2 protein and
mRNA levels and decreased DJ-1 levels in cases of severe
COPD [28].
The maintenance of GSH in the epithelial lining fluid
(ELF) and its elevation in the ELF of smokers [29-31] are
poorly understood. GSH is transported from the cells by
GST pi and mu immunoreactivities in human lung Figure 4
GST pi and mu immunoreactivities in human lung. A. In Western analysis of GST pi in lung homogenates, the level of 
GST pi was elevated in Stage I-II COPD compared to that in healthy smokers (p = 0.002). B. In immunohistochemical staining, 
GST pi was mainly expressed in the epithelium of airways and alveoli. C. Western analysis of the lung homogenates for GST mu 
showed some variability but the difference between the groups was not significant (p = 0.063). C. In immunohistochemical 
staining, GST mu was located in the macrophages; the expression in bronchial and alveolar epithelium was weak.Respiratory Research 2008, 9:80 http://respiratory-research.com/content/9/1/80
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multiple mechanisms including GST dependent detoxifi-
cation reactions. In the extracellular milieu, GSH can be
bound to proteins and/or be further degraded to amino
acids which then move inside the cells to participate in
GSH re-synthesis. The toxins present in the cigarette
smoke can be transported from the cells by GSTs in reac-
tions that consume GSH. The expression of GST alpha and
pi in induced sputum supernatants suggests that after ini-
tial induction which occurs via a Nrf2 mediated mecha-
nism, GSTs, at least GST alpha, pi and omega [8] can be
exported/secreted to the extracellular space. The GSTs in
the sputum supernatant fractions observed in this study
and in earlier studies are not artifacts related to cell disrup-
tion during the isolation, since other intracellular markers
for cell lysis were negative [20]. GSTs, in combination
with GSH which can also be released from the proteins by
glutaredoxin, can further detoxify a number of reactive
compounds in the extracellular milieu. This initial
increase followed by the subsequent decline of several
enzymes related to GSH synthesis/homeostasis including
GST in COPD as shown in this study and in the previous
investigations parallels with the initial induction and con-
sequent dysfunction of the Nrf2 pathway in COPD lungs.
To conclude, this study on GSTs shows the presence of
GST alpha especially in mild/moderate COPD. These
results combined with previous studies on the major anti-
oxidant enzymes suggest early induction but consequent
decline of antioxidant defense systems related to the Nrf2
pathway in severe/very severe COPD. This study remarka-
bly extends earlier observations since this is also the first
one in detecting elevated GST alpha levels in the sputum
supernatants in chronic bronchitis and in COPD a situa-
tion with documented increased oxidant burden and
inflammation of the airways.
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